Table 1.
Clinicopathological features of the overall population at diagnosis.
| N (%) or median (Q1–Q3) | |
|---|---|
| Total | 547 (100) |
| Age at primary BC diagnosis (yy), median (Q1–Q3) | 51.6 (43.4–62.6) |
| Primary BC histotype | |
| Ductal | 437 (79.9) |
| Non-ductal | 104 (19.0) |
| Missing | 6 (1.1) |
| Primary BC histologic grade | |
| 1 | 27 (5.0) |
| 2 | 187 (34.2) |
| 3 | 308 (56.3) |
| Missing | 25 (4.5) |
| Stage at BC diagnosis | |
| Early | 509 (93.1) |
| Stage IV | 32 (5.9) |
| Missing | 6 (1.1) |
| Primary BC phenotype | |
| HR + /HER2− | 336 (61.4) |
| Triple-negative | 79 (14.5) |
| HER2 + | 132 (24.1) |
| Missing | 0 (0.0) |
| Treatment for early BC | |
| Adjuvant | |
| Chemotherapy | 282 (51.5) |
| Hormonal therapy | 350 (64.0) |
| Anti-HER2 | 68 (12.4) |
| Neoadjuvant | |
| Chemotheapy | 151 (27.6) |
| Hormonal therapy | 14 (2.5) |
| Anti-HER2 | 37 (6.8) |
| Treatment for relapsed/stage IV BC | |
| Chemotherapy | 430 (78.6) |
| Hormonal therapy | 364 (66.5) |
| Anti-HER2 | 40 (7.3) |
| 131 (23.9) | |
| Time from primary BC diagnosis and BC relapse (mo), median (Q1-Q3) | 39.4 (20.3–81.5) |
| Time from recurrent BC diagnosis and biopsy of relapse (mo), median (Q1-Q3) | 0.2 (0.0–6.9) |
BC breast cancer, yy years, Q quartile, HR + /HER2 + , hormone-receptor positive/HER2-negative, mo months